Considering the first-line setting of NSCLC, ICI-monotherapy is strictly driven by a PD-L1 tumor proportion score (TPS) ≥ 50%, since an advantage in OS, as compared to platinum-based chemotherapy, has been observed only in this situation. The gene discussed is CD274; the disease is neoplasm.